NewAmsterdam Pharma (NAMSW) Return on Equity (2023 - 2025)
Historic Return on Equity for NewAmsterdam Pharma (NAMSW) over the last 3 years, with Q3 2025 value amounting to 0.29%.
- NewAmsterdam Pharma's Return on Equity rose 2300.0% to 0.29% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.29%, marking a year-over-year increase of 2300.0%. This contributed to the annual value of 0.46% for FY2024, which is 300.0% up from last year.
- NewAmsterdam Pharma's Return on Equity amounted to 0.29% in Q3 2025, which was up 2300.0% from 0.21% recorded in Q2 2025.
- In the past 5 years, NewAmsterdam Pharma's Return on Equity ranged from a high of 0.21% in Q2 2025 and a low of 0.57% during Q2 2024
- In the last 3 years, NewAmsterdam Pharma's Return on Equity had a median value of 0.43% in 2024 and averaged 0.39%.
- As far as peak fluctuations go, NewAmsterdam Pharma's Return on Equity tumbled by -2700bps in 2024, and later skyrocketed by 3600bps in 2025.
- Quarter analysis of 3 years shows NewAmsterdam Pharma's Return on Equity stood at 0.45% in 2023, then increased by 5bps to 0.43% in 2024, then soared by 31bps to 0.29% in 2025.
- Its Return on Equity stands at 0.29% for Q3 2025, versus 0.21% for Q2 2025 and 0.24% for Q1 2025.